ABSTRACT
Background The treatment of severe aortic stenosis has evolved considerably since the introduction of transcatheter aortic valve replacement (TAVR), yet trends in in-hospital complications for patients undergoing TAVR or surgical aortic valve replacement (SAVR) at a national level have yet to be evaluated.
Methods We performed a retrospective cohort study using Medicare data to evaluate temporal trends in complications among beneficiaries aged ≥65 years treated with elective isolated transfemoral TAVR or SAVR between 2012 and 2019. The study endpoint was the occurrence of a major complication during the index AVR hospitalization, defined as a composite outcome. Multivariable logistic regression was used to assess odds of complications for TAVR and SAVR, individually over time, after adjusting for baseline characteristics. Another risk-adjusted model assessed the risk of complications for TAVR vs SAVR, over time.
Results The cohort included 211,212 patients (mean age:78.6±7.3 years, female:45.0%). Complication rates following elective isolated AVR decreased from 49% in 2012 to 22% in 2019. These reductions were more pronounced for TAVR (41%->19%, delta=22%) than SAVR (51%->47%, delta=4%). After risk adjustment, the risk of any complication with TAVR was 47% (p<0.0001) lower compared to SAVR in 2012, and 78% (p<0.0001) lower in 2019. TAVR was independently associated with reduced odds of complications each year compared to 2012, with the magnitude of benefit increasing over time (2013 vs 2012: OR=0.89(0.81-0.97); 2019 vs 2012: OR=0.35(0.33-0.38)).
Conclusions Between 2012-2019, the risk of complications after AVR among Medicare beneficiaries decreased significantly, with larger absolute and relative changes among patients treated with TAVR than SAVR.
Competing Interest Statement
William Irish, Candace Gunnarsson and Michael Ryan are paid consultants to Edwards Lifesciences. Soumya Chikermane and Christin Thompson are Edwards Lifesciences employees. James E. Harvey ? Abiomed: Proctor, Speaker?s bureau, Avail: Advisory board, Boston Scientific: Advisory board, Proctor, Speaker?s bureau, Medtronic: Advisory board, Proctor, Speaker?s bureau, Opsens: Advisory board Samir R. Kapadia ? nothing to disclose. David J. Cohen ? Consulting Services: Medtronic; Edwards Lifesciences; Abbott Vascular; Boston Scientific; Svelte, Inc.; Corvia Medical; Impulse Dynamics; AngioInsight; HeartBeam. Research Grant Support: Edwards Lifesciences; Abbott Vascular; Corvia Medical; National Heart, Lung, and Blood Institute; Philips, Inc.; Svelte, Inc.; Brain-Q; St. Paul?s Hospital; V-Wave, Inc; Saranas, Inc.; I-Rhythm, Inc.; Zoll Medical; CathWorks; Ancora. Ankur Kalra - Speaker: Bristol Myers Squibb and Educational Grant: Radcliffe Medical Media, UK for the cardiology podcast show, Parallax Rishi Puri -Consultant to Medtronic, Abbott and Products & Features
Funding Statement
This study was funded by Edwards Lifesciences. The external authors and study sponsors participated in the study design, data analysis, data interpretation, and development of the report, and gave approval to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used to perform this analysis were de-identified and accessed in compliance with the Health Insurance Portability and Accountability Act. As a retrospective analysis of a de-identified database, the research was exempt from IRB review under 45 CFR 46.101(b), and the need for individual patient consent was waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This study was sponsored by Edwards Lifesciences.
The external authors and study sponsors participated in the study design, data analysis, data interpretation, and development of the report, and gave approval to submit for publication.
Relevant industry relationships and financial interests are as follows:
William Irish, Candace Gunnarsson and Michael Ryan are paid consultants to Edwards Lifesciences.
Soumya Chikermane and Christin Thompson are Edwards Lifesciences employees.
James E. Harvey – Abiomed: Proctor, Speaker’s bureau, Avail: Advisory board, Boston Scientific: Advisory board, Proctor, Speaker’s bureau, Medtronic: Advisory board, Proctor, Speaker’s bureau, Opsens: Advisory board
Samir R. Kapadia – nothing to disclose.
David J. Cohen – Consulting Services: Medtronic; Edwards Lifesciences; Abbott Vascular; Boston Scientific; Svelte, Inc.; Corvia Medical; Impulse Dynamics; AngioInsight; HeartBeam. Research Grant Support: Edwards Lifesciences; Abbott Vascular; Corvia Medical; National Heart, Lung, and Blood Institute; Philips, Inc.; Svelte, Inc.; Brain-Q; St. Paul’s Hospital; V-Wave, Inc; Saranas, Inc.; I-Rhythm, Inc.; Zoll Medical; CathWorks; Ancora.
Ankur Kalra - Speaker: Bristol Myers Squibb and Educational Grant: Radcliffe Medical Media, UK for the cardiology podcast show, Parallax
Rishi Puri -Consultant to Medtronic, Abbott and Products & Features
Data Availability
This retrospective cohort study used Medicare fee for service (FFS) data accessed through a license agreement and is not able to be posted to a website.
